Director of Organogenesis Holdings Inc. Sells $127,500 in Stock

On March 4, 2023, Michael Joseph Driscoll, a director at Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report), sold 25,000 shares of the company's stock. The shares were sold at an average price of $5.10 each, resulting in a total transaction value of $127,500.00. After this sale, Driscoll's direct ownership in Organogenesis has decreased to 166,879 shares, which are presently valued at approximately $851,082.90. This transaction reflects a significant 13.03% reduction in his stake in the company. The details of the sale were filed with the Securities and Exchange Commission (SEC) and can be found in their records.

Organogenesis Stock Performance

On Thursday, the stock price of Organogenesis (NASDAQ:ORGO) experienced a decline, trading down by 6.2% or $0.37, reaching a price of $5.64. During this trading session, the volume of shares traded was 1,263,723, which is higher than the average volume of 1,066,552 shares. Currently, the company has a market capitalization of approximately $715.31 million. The stock's price-to-earnings (P/E) ratio stands at -94.00, and it has a beta of 1.66. Financial metrics show a debt-to-equity ratio of 0.21, with a current ratio of 3.09 and a quick ratio of 2.74. Over the past year, Organogenesis's stock has seen a low of $2.17 and a high of $6.71. As of the latest figures, the fifty-day simple moving average for the stock is $3.61, while the two-hundred-day simple moving average is $3.33.

Institutional Investments in Organogenesis

Recently, several hedge funds and institutional investors have made changes to their holdings in Organogenesis. Virtu Financial LLC acquired a new position in the company during the fourth quarter, valued at around $38,000. Similarly, Captrust Financial Advisors and Intech Investment Management LLC purchased new shares in the company, valued at approximately $36,000 and $43,000, respectively. Palumbo Wealth Management LLC also joined the group of new investors in the fourth quarter with an investment valued at around $65,000. Additionally, ProShare Advisors LLC increased its stake in Organogenesis by 49.0% during the fourth quarter and currently holds about 20,329 shares of the company, valued at about $65,000. Institutional investors overall hold approximately 49.57% of the company's shares.

Analyst Ratings and Price Targets

In development news, Morgan Stanley has raised its price target for Organogenesis shares from $4.00 to $6.00 and has assigned the stock an "equal weight" rating in a recent research report.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a company specializing in regenerative medicine. It is engaged in the development, manufacturing, and commercialization of advanced solutions for wound care, surgical applications, and sports medicine within the United States. Some of its advanced wound care products include Affinity, a type of amniotic membrane; Novachor, a chorion membrane; Apligraf, a bioengineered cell therapy; and Dermagraft, a bioengineered product that generates human collagen and growth factors.

Organogenesis, Stock, Sale